期刊论文详细信息
| Frontiers in Pharmacology | 卷:12 |
| Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety | |
| 关键词: advocacy program; centralised regulatory procedure; hybrid application; nanomedicines; nanosimilars; follow-on products; | |
| DOI : 10.3389/fphar.2021.787239 | |
| 来源: DOAJ | |
【 摘 要 】
【 授权许可】
Unknown